Akoya Biosciences (AKYA) News Today $2.16 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Akoya Biosciences (NASDAQ:AKYA) Given "Overweight" Rating at Piper SandlerPiper Sandler reiterated an "overweight" rating and issued a $3.00 price target (down from $4.00) on shares of Akoya Biosciences in a research note on Tuesday.November 19 at 12:23 PM | marketbeat.comAkoya Biosciences (NASDAQ:AKYA) Given New $3.50 Price Target at Canaccord Genuity GroupNovember 18 at 1:35 AM | americanbankingnews.comTime To Worry? Analysts Just Downgraded Their Akoya Biosciences, Inc. (NASDAQ:AKYA) OutlookNovember 17, 2024 | finance.yahoo.comAkoya Biosciences (NASDAQ:AKYA) Downgraded to Hold Rating by Craig HallumNovember 17, 2024 | americanbankingnews.comCraig-Hallum Downgrades Akoya Biosciences (AKYA)November 16, 2024 | msn.comAkoya Biosciences Shares Sink After FY24 Outlook CutNovember 15, 2024 | marketwatch.comAkoya Biosciences Inc (AKYA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...November 15, 2024 | finance.yahoo.comAkoya Biosciences Reports Q3 2024 Financial ResultsNovember 15, 2024 | markets.businessinsider.comAkoya Biosciences downgraded to Hold from Buy at Craig-HallumNovember 15, 2024 | markets.businessinsider.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | msn.comCanaccord Genuity Group Has Lowered Expectations for Akoya Biosciences (NASDAQ:AKYA) Stock PriceCanaccord Genuity Group dropped their price target on Akoya Biosciences from $6.00 to $3.50 and set a "buy" rating on the stock in a research report on Friday.November 15, 2024 | marketbeat.comAkoya Biosciences (NASDAQ:AKYA) Stock Rating Lowered by Craig HallumCraig Hallum lowered Akoya Biosciences from a "buy" rating to a "hold" rating and reduced their price target for the stock from $7.00 to $5.00 in a research report on Friday.November 15, 2024 | marketbeat.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Sees Large Decline in Short InterestAkoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) was the recipient of a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 1,600,000 shares, a decline of 20.8% from the October 15th total of 2,020,000 shares. Approximately 7.8% of the company's shares are short sold. Based on an average trading volume of 132,000 shares, the short-interest ratio is currently 12.1 days.November 15, 2024 | marketbeat.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsNovember 15, 2024 | americanbankingnews.comAkoya Biosciences, Inc. (AKYA) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comAkoya Biosciences Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | globenewswire.comCraig-Hallum Sticks to Its Buy Rating for Akoya Biosciences (AKYA)November 12, 2024 | markets.businessinsider.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Recommendation of "Moderate Buy" by AnalystsAkoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) has earned an average rating of "Moderate Buy" from the nine research firms that are presently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and five have assigned a buy recommendatioNovember 10, 2024 | marketbeat.comAkoya Biosciences (AKYA) Scheduled to Post Quarterly Earnings on ThursdayAkoya Biosciences (NASDAQ:AKYA) will be releasing earnings after the market closes on Thursday, November 14, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=640894)November 7, 2024 | marketbeat.comAkoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO PanelNovember 6, 2024 | markets.businessinsider.comAkoya Biosciences unveils new era in spatial content innovationNovember 6, 2024 | markets.businessinsider.comAkoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024October 28, 2024 | globenewswire.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nine research firms that are presently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and fivOctober 16, 2024 | marketbeat.comAkoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer ImmunotherapyOctober 9, 2024 | markets.businessinsider.comAkoya Biosciences (NASDAQ:AKYA) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comAkoya's Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer ImmunotherapyOctober 7, 2024 | globenewswire.comAkoya Biosciences Announces Appointment Of Scott Mendel As Chairman Of The Board Of DirectorsOctober 3, 2024 | markets.businessinsider.comAkoya Biosciences Announces Scott Mendel as Chairman of the Board of DirectorsOctober 3, 2024 | globenewswire.comShort Interest in Akoya Biosciences, Inc. (NASDAQ:AKYA) Declines By 6.4%Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 3,090,000 shares, a decrease of 6.4% from the August 31st total of 3,300,000 shares. Currently, 14.0% of the company's stock are sold short. Based on an average daily volume of 182,500 shares, the short-interest ratio is presently 16.9 days.September 30, 2024 | marketbeat.comCraig-Hallum Reaffirms Their Buy Rating on Akoya Biosciences (AKYA)September 14, 2024 | markets.businessinsider.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Up 6.3% in AugustAkoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) saw a large increase in short interest in August. As of August 15th, there was short interest totalling 3,360,000 shares, an increase of 6.3% from the July 31st total of 3,160,000 shares. Currently, 15.2% of the company's stock are sold short. Based on an average trading volume of 272,000 shares, the short-interest ratio is presently 12.4 days.September 2, 2024 | marketbeat.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the nine research firms that are currently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and five havAugust 27, 2024 | marketbeat.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Up 6.4% in JulyAkoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) was the recipient of a significant increase in short interest in July. As of July 31st, there was short interest totalling 3,160,000 shares, an increase of 6.4% from the July 15th total of 2,970,000 shares. Currently, 14.3% of the company's stock are short sold. Based on an average trading volume of 363,600 shares, the days-to-cover ratio is presently 8.7 days.August 18, 2024 | marketbeat.comPiper Sandler Trims Akoya Biosciences (NASDAQ:AKYA) Target Price to $4.00Piper Sandler decreased their price target on shares of Akoya Biosciences from $6.00 to $4.00 and set an "overweight" rating on the stock in a report on Tuesday.August 13, 2024 | marketbeat.comCapital One Financial Research Analysts Boost Earnings Estimates for Akoya Biosciences, Inc. (NASDAQ:AKYA)Akoya Biosciences, Inc. (NASDAQ:AKYA - Free Report) - Investment analysts at Capital One Financial lifted their FY2024 earnings per share estimates for Akoya Biosciences in a research note issued on Tuesday, August 6th. Capital One Financial analyst T. Chiang now expects that the company will earAugust 8, 2024 | marketbeat.comMorgan Stanley Downgrades Akoya Biosciences (AKYA)August 7, 2024 | msn.comBTIG Downgrades Akoya Biosciences (AKYA)August 7, 2024 | msn.comAkoya Biosciences, Inc.: Akoya Biosciences Reports Second Quarter 2024 Financial ResultsAugust 7, 2024 | finanznachrichten.deHold Rating on Akoya Biosciences Amidst Solid Operations and Market HeadwindsAugust 7, 2024 | markets.businessinsider.comAkoya Biosciences, Inc. (AKYA) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | seekingalpha.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | msn.comJP Morgan Downgrades Akoya Biosciences (AKYA)August 6, 2024 | msn.comAkoya Biosciences (NASDAQ:AKYA) Cut to "Equal Weight" at Morgan StanleyMorgan Stanley downgraded shares of Akoya Biosciences from an "overweight" rating to an "equal weight" rating in a research note on Tuesday.August 6, 2024 | marketbeat.comAkoya Biosciences (NASDAQ:AKYA) Issues Quarterly Earnings ResultsAkoya Biosciences (NASDAQ:AKYA - Get Free Report) issued its earnings results on Monday. The company reported ($0.27) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.27). Akoya Biosciences had a negative net margin of 72.68% and a negative return on equity of 111.80%. The business had revenue of $23.16 million during the quarter, compared to the consensus estimate of $23.61 million. During the same period last year, the business posted ($0.51) EPS.August 6, 2024 | marketbeat.comAkoya Biosciences Reports Second Quarter 2024 Financial ResultsAugust 5, 2024 | globenewswire.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Given Average Rating of "Moderate Buy" by BrokeragesShares of Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation aAugust 2, 2024 | marketbeat.comSilvercrest Asset Management Group LLC Takes $2.72 Million Position in Akoya Biosciences, Inc. (NASDAQ:AKYA)Silvercrest Asset Management Group LLC purchased a new position in shares of Akoya Biosciences, Inc. (NASDAQ:AKYA - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 580,834 shares of the comJuly 31, 2024 | marketbeat.comAKYA Aug 2024 2.500 put (AKYA240816P00002500)July 30, 2024 | finance.yahoo.comAkoya Biosciences: Poised for Recovery and Growth Amidst Market ChallengesJuly 19, 2024 | markets.businessinsider.comAkoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor ConferencesJuly 15, 2024 | globenewswire.com Get Akoya Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter. Email Address My #1 Pre IPO Trade for 2025 – NAME and TICKER (Ad)One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report... The Next SpaceX Pre-IPO AKYA Media Mentions By Week AKYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKYA News Sentiment▼-0.180.45▲Average Medical News Sentiment AKYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKYA Articles This Week▼212▲AKYA Articles Average Week Get Akoya Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PRLD News Today STRO News Today QTRX News Today AEHR News Today NAUT News Today QSI News Today SENS News Today SEER News Today FEIM News Today KEQU News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKYA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akoya Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akoya Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKYA Stock Alerts